This second day play has massive potential 🚀

These setups look primed!                                                                                                                                                                                                                                                                                                                                                                                                                 February 13, 2023 | [Read Online]( Good day, 360 – Here are our top 3 trade ideas today – these setups look primed! And don't forget to check out our Economic Calendar below. Be the best prepared trader on the Street! XPON - 2nd day play. Closed up 50% after announcing it would be exclusive supplier of lithium-ion batteries for Cube Series camper CLNN - Trades 70% higher in pre-market after Phase 2 success in Multiple Sclerosis study FSLY - B of A Securities upgrades Fastly to Buy, raises price target from $10.50 to $16 A message from [BioTech Stock Market News](* 🔥 Hot Stock of the Day 🔥 The market is buzzing about the potential of this [tiny $3 stock right now](. They have recently signed a definitive agreement to acquire a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million, and over 600,000 tests completed since inception. The stock has made some [SERIOUS moves in the last few months](, and it will be exciting to see where it goes next… You can see that [Yahoo Finance]( is showing several bullish indicators that are flashing green lights right now ✅ Learn more about this innovative company by [visiting this page now](. But don’t wait too long… an [opportunity at these levels]( might be gone before you know it! XPON - 2nd day play. Closed up 50% after announcing it would be exclusive supplier of lithium-ion batteries for Cube Series camper Expion 360 (XPON) announced it would be the exclusive supplier of lithium-ion batteries for an ultra-lightweight foldable camper made by Cube Series. Cube Series campers are compatible with trucks such as Rivian. XPON opened on its IPO day around $8 and was trading at $2 before the news. It closed yesterday at $3.08 on volume of over 60 million shares and is gapping another 20% higher this morning. According to Finviz, the stock only has a float of 3.34 million shares, so traded almost 20 times the float on Friday. With a market cap of only $13.61 million at yesterday’s close, there is plenty of potential for this company to be revalued in the short-term. Friday’s high of $3.75 should prove to be an important inflection point today. XPON has failed there on 3 occasions since December. Above it the first target will be the pre-market high of $3.94. A break of $4 puts $4.50, then $5 and $5.30 in play above that. Given the small float and extreme volume there is no telling how high this can go if it catches. Below $3.75 there is potential support at $3.08 which would be a gap fill. The next target would be $2.85 and $2.50 below that. This move began at $2. Clene (CLNN) today announced updated MRI results from the Phase 2 double-blinded, 48-week treatment period of the VISIONARY-MS trial in multiple sclerosis (MS) patients. These exploratory MRI results: - reinforced the clinical neurological improvements previously reported - showed improved brain neuronal structural integrity, independent of an immunomodulatory effect - showed decreased brain deterioration The brain improvements in stable MS patients on background therapy appear unprecedented. CLNN was trading above $10 back in 2021. The first target for bulls is the pre-market high of $2.43. Above that there is a gap to fill at $2.80. The next major resistance level above that is $3.19 with $3.50 and $3.80 above that. Below $2.43 there is potential support at $1.90, then $1.70 and a gap to fill at $1.34. FSLY - B of A Securities upgrades Fastly to Buy, raises price target from $10.50 to $16 Bank of America has a huge investor base, both retail and institutional so upgrades should be taken note of. B of A Securities upgraded FSLY from Underperform to Buy, raising the price target to $16. FSLY is now on millions of investors' radars, and this could introduce new order flow. FSLY is gapping 8% higher this morning on the upgrade. Given the price target is more than 50% higher than current prices there is plenty of upside in the name and the potential for a trend day. $10.80 was the pre-market high and should be an important pivot level today. $11 was a major prior resistance area, with $11.50 and $12 the next targets above that. Below $10.80, there is potential support at the $10.14-$10.10 area with a gap to fill at $9.87 below that. Economic Calendar (EST) 11:30am 3-6 Month Bill Auction Remember Tuesday at 8:30am is CPI numbers. Earnings for Today (After Market) ACGL, AEMD, AIN, AMKR, ANET, ANGI, ARKR, BLKB, BRX, CAR, CDNS, CGRN, DENN, ES, FE, IAC, ICMB, IFS,INST, KRG, LSCC, MEDP, MKSI, MRC, NOTV, NTB, OM, OTTR, PLTR, QIPT, RBOT, SEDG, SEVN, SKYT, VNO Top Headlines META has delayed finalizing multiple teams’ budgets while it prepares a fresh round of job cuts. RGNX: REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process BGRY: Berkshire Grey Inc. (Nasdaq: BGRY), (“Berkshire Grey” or the “Company”), a leader in AI-enabled robotic solutions that automate supply chain processes, today confirmed that it has received a non-binding indication of interest from SoftBank Group Corp. (“SoftBank”) to acquire all the outstanding capital stock of the Company for $1.30 per share in cash. GTHX: G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) AULT: Ault Alliance Announces Record Preliminary 2022 Revenue of $134 Million, up 156% from 2021 LEV: Lion Electric Announces North American Agreement with Mitsubishi HC Capital Canada and ENGS Commercial Finance Co. to Provide Financing for All-electric Buses and Medium- and Heavy-Duty Trucks Through LionCapital Solutions NRXP: NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality ZG: Evercore ISI upgrades Zillow Group, says real estate stock could jump 40% on a 'rapid recovery' in the housing market – CNBC HOOK: HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers CLNN: Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity TNXP: Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies TLRY: Good Supply Cannabis Brand Launches New Product Lineup HILS: Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer IRWD: Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old GRCL: Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma PRVB: Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US PHIO: Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements DGX: Cleveland Diagnostics Announces Agreement with Quest Diagnostics to Expand Patient Access to IsoPSA® Prostate Cancer Testing ANPC: AnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S. NVAX: U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine SEEL: Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform MDRX: Veradigm and HealthVerity Collaborate to Advance Real-World Evidence and Care for Patients with Cardiovascular Disease and Diabetes EXEL: Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors OCUP: Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis COMS: COMSovereign Announces an 80% Year-Over-Year Reduction of Outstanding Secured Debt AUID: authID® Expands Verified™ CloudConnect™ to BeyondTrust, Bringing Unphishable Human Factor Authentication™ to Privileged Access Management MAIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition ABOS: Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease CRL: Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein To Your Success! *Please see disclosures below. 62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions DISCLAIMER: To more fully understand RagingBull.com, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at [(. *ISSUER-PAID ADVERTISEMENT. RagingBull has been paid ten thousand dollars cash by Lifewater Media for advertising [BioTech Stock Market News](. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Raging Bull nor any of its owners, employees OR INDEPENDENT CONTRACTORS is CURRENTLY registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements.In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 lee, NH 03861, United States [Publish on Beehiiv](